InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,223.34
(
0.18%
)
US TECH 100
17,688.40
(
0.27%
)
Dow Jones
39,527.46
(
0.35%
)
Brent Oil
82.76
(
-1.42%
)
Bitcoin
60,624.76
(
-3.84%
)
Post# of 30310
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

~ Blue ~

Send PM Follow Ignore
Followers 2576
Posts 112748
Boards Moderated 1
Alias Born 08/25/2010

~ Blue ~

Re: None

Wednesday, 08/19/2015 12:29:20 AM

Wednesday, August 19, 2015 12:29:20 AM

Post# of 30310
AEZS~ A Potential Breakthrough in Cancer Therapy Product
?
New Chemical Entity (NCE) composed of a targeted synthetic peptide carrier
linked to doxorubicin
?
Value proposition:
Improved, targeted
delivery of doxorubicin with improved
benefit
-risk profile
Status
?ZoptEC Phase 3 trial in endometrial cancer
–Fully enrolled (over 500 patients) / over 120 active sites in North America,
Europe and Israel
–CRO Ergomed to assume 30% up to $10 million of clinical and reg. costs
–1st Interim Results: DSMB
recommendation to continue
ZoptECtrial, April 2015
–2nd Interim Results: Expected October 2015

http://www.aezsinc.com/pdfdyn/AEZS%20Presentation%20AUG-2015-FINAL.pdf

follow me on BLUE SKY BREAKOUT

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up